Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript

On Thursday, Evaxion Biotech (NASDAQ:EVAX) discussed second-quarter financial results during its ear

Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.01) per share which beat the analyst

COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage Tech

Webull Corp (NASDAQ: BULL) rose sharply in pre-market trading after reporting better-than-expected Q

Gainers BioVie (NASDAQ:BIVI) stock increased by 15.7% to $1.55 during Wednesday's after-market

EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient

COPENHAGEN, Denmark, August 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage Tech

COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage Tech

Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatm

COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBi

The new data demonstrates the potential to improve control of acute infection, latency, and viral re

COPENHAGEN, Denmark, July 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBi

New preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine c

COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio

COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBi

EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activat

COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBi

Data will reflect the functional characterization of EVX-04Poster presentation on June 13, 2026COPEN

COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio

Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript

Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.01) per share which beat the analyst

COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio

COPENHAGEN, Denmark, May 4, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio

Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel va

COPENHAGEN, Denmark, April 27, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechB

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Bu

Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vac

COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechB

Data analysis conducted in collaboration with a leading academic medical center shows that AI‑Immuno

COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechB

EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melano

Shares of Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report) have received a consensus rat

COPENHAGEN, Denmark, March 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechB

COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechB

Lake Street analyst Thomas Flaten maintains Evaxion (NASDAQ:EVAX) with a Buy and lowers the price

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Bu

Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report) has received a consensus recommendation

Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.02) per share which beat the analyst

Merck declines its option on Evaxion's EVX-B2 gonorrhea vaccine, leaving global rights with Evax

Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targe

Evaxion's AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce vi

Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in deve

Evaxion Biotech (NASDAQ:EVAX) reported quarterly earnings of $0.01 per share which beat the analyst